
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics Inc., a development-stage biotechnology company, is focused on advancing antiviral therapies that address virus-triggered immune responses, particularly for conditions like fibromyalgia and long COVID. The company's strong potential for future revenues has prompted an increase in financial projections, with analysts raising their 12-month price target from $10 to $12 per share. Additionally, the recent licensing agreement with Serpin Pharma for the global rights to SP16 in cancer-related pain indications further enhances Dogwood's growth prospects and market positioning.
Bears say
Dogwood Therapeutics Inc, previously known as Virios Therapeutics Inc, operates as a development-stage biotechnology firm concentrating on antiviral therapies for conditions like fibromyalgia and long COVID. The company has yet to demonstrate significant revenue generation or market penetration, raising concerns regarding its long-term financial viability and the commercial success of its lead product candidates IMC-1 and IMC-2. Additionally, the ongoing challenges related to clinical development timelines and regulatory approvals may hinder investor confidence and contribute to a more negative market perception of its stock.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares